Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Average PT from Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) have been given an average rating of "Moderate Buy" by the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $56.33.

A number of equities analysts recently weighed in on the company. Leerink Partners cut Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $60.00 to $56.00 in a report on Friday, September 27th. StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, November 9th. Royal Bank of Canada increased their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a report on Tuesday, December 10th. Scotiabank lifted their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, December 9th. Finally, Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 27th.

Agios Pharmaceuticals Trading Up 1.1 %

AGIO traded up $0.35 on Friday, reaching $32.19. The stock had a trading volume of 881,852 shares, compared to its average volume of 767,276. The business's 50-day moving average price is $47.63 and its two-hundred day moving average price is $45.77. The company has a market cap of $1.84 billion, a P/E ratio of 2.83 and a beta of 0.87. Agios Pharmaceuticals has a 12-month low of $20.96 and a 12-month high of $62.58.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of AGIO. Bank of New York Mellon Corp boosted its stake in Agios Pharmaceuticals by 13.9% during the second quarter. Bank of New York Mellon Corp now owns 223,151 shares of the biopharmaceutical company's stock worth $9,622,000 after buying an additional 27,193 shares during the last quarter. TD Asset Management Inc grew its holdings in shares of Agios Pharmaceuticals by 34.6% in the second quarter. TD Asset Management Inc now owns 210,472 shares of the biopharmaceutical company's stock valued at $9,076,000 after purchasing an additional 54,054 shares during the period. North Star Asset Management Inc. acquired a new stake in Agios Pharmaceuticals during the second quarter worth about $216,000. Candriam S.C.A. acquired a new stake in Agios Pharmaceuticals during the second quarter worth about $13,922,000. Finally, Acadian Asset Management LLC acquired a new position in Agios Pharmaceuticals in the 2nd quarter valued at about $37,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.